163 related articles for article (PubMed ID: 34609300)
1. Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer.
Yoruker EE; Ozgur E; Keskin M; Ozgur I; Gezer U
Turk J Gastroenterol; 2021 Sep; 32(9):720-726. PubMed ID: 34609300
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery.
Zhang X; Wu Z; Shen Q; Li R; Jiang X; Wu J; Li D; Wang D; Zou C; Zhong Y; Cheng X
Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):111-117. PubMed ID: 31880527
[TBL] [Abstract][Full Text] [Related]
3. Liquid Biopsy in Gastric Cancer: Analysis of Somatic Cancer Tissue Mutations in Plasma Cell-Free DNA for Predicting Disease State and Patient Survival.
Varkalaite G; Forster M; Franke A; Kupcinskas J; Skieceviciene J
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00403. PubMed ID: 34644276
[TBL] [Abstract][Full Text] [Related]
4. Methylation status and long-fragment cell-free DNA are prognostic biomarkers for gastric cancer.
Ko K; Kananazawa Y; Yamada T; Kakinuma D; Matsuno K; Ando F; Kuriyama S; Matsuda A; Yoshida H
Cancer Med; 2021 Mar; 10(6):2003-2012. PubMed ID: 33641249
[TBL] [Abstract][Full Text] [Related]
5. Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer.
Waki K; Yokomizo K; Yoshiyama K; Takamori S; Komatsu N; Yamada A
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):176-182. PubMed ID: 33541161
[TBL] [Abstract][Full Text] [Related]
6. Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors.
Oversoe SK; Sorensen BS; Tabaksblat EM; Gronbaek H; Kelsen J
Neuroendocrinology; 2022; 112(1):43-50. PubMed ID: 33461190
[TBL] [Abstract][Full Text] [Related]
7. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.
Yu Z; Qin S; Wang H
J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389
[TBL] [Abstract][Full Text] [Related]
8. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
9. Enhanced detection of cell-free DNA (cfDNA) enables its use as a reliable biomarker for diagnosis and prognosis of gastric cancer.
Bu J; Lee TH; Jeong WJ; Poellmann MJ; Mudd K; Eun HS; Liu EW; Hong S; Hyun SH
PLoS One; 2020; 15(12):e0242145. PubMed ID: 33264292
[TBL] [Abstract][Full Text] [Related]
10. The Ratio of ssDNA to dsDNA in Circulating Cell-Free DNA Extract is a Stable Indicator for Diagnosis of Gastric Cancer.
Huang X; Zhao Q; An X; Pan J; Zhao L; Shen L; Xu Y; Yuan D
Pathol Oncol Res; 2020 Oct; 26(4):2621-2632. PubMed ID: 32632900
[TBL] [Abstract][Full Text] [Related]
11. Quantification of plasma cell-free DNA levels in dogs with various tumors.
Tagawa M; Shimbo G; Inokuma H; Miyahara K
J Vet Diagn Invest; 2019 Nov; 31(6):836-843. PubMed ID: 31585514
[TBL] [Abstract][Full Text] [Related]
12. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
13. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
14. Determination of serum RP11-731F5.2 as a noninvasive biomarker for gastric cancer diagnosis and prognosis.
Jing R; Liu S; Jiang Y; Zong W; Ju S; Cui M
Pathol Res Pract; 2020 Dec; 216(12):153261. PubMed ID: 33176259
[TBL] [Abstract][Full Text] [Related]
15. Quantification of mitochondrial cfDNA reveals new perspectives for early diagnosis of colorectal cancer.
Linke C; Hunger R; Reinwald M; Deckert M; Mantke R
BMC Cancer; 2023 Mar; 23(1):291. PubMed ID: 36997875
[TBL] [Abstract][Full Text] [Related]
16. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
17. Genome-Scale Methylation Analysis of Circulating Cell-Free DNA in Gastric Cancer Patients.
Ren J; Lu P; Zhou X; Liao Y; Liu X; Li J; Wang W; Wang J; Wen L; Fu W; Tang F
Clin Chem; 2022 Feb; 68(2):354-364. PubMed ID: 34791072
[TBL] [Abstract][Full Text] [Related]
18. Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma.
Eskander NS; Mansour L; Abdelaal A; Saad E; Mohamed D
Asian Pac J Cancer Prev; 2022 Jan; 23(1):339-348. PubMed ID: 35092403
[TBL] [Abstract][Full Text] [Related]
19. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL
Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961
[TBL] [Abstract][Full Text] [Related]
20. Cell-free DNA as a biomarker for colorectal cancer: a retrospective analysis in patients before and after surgery.
Zhong Y; Zhou Q; Zhang Y; Zhou S; Zhang G; Jiang C; Zhang Z; Zhang X; Xu J; Jin C; Cao L; Chen L
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):135-141. PubMed ID: 32415940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
